Family · Pharmaceutical analytical standards
Osimertinib
A third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR mutations, including the T790M resistance mutation; approved in the United States in November 2015. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Designed from 2009 onwards, it binds irreversibly to cysteine 797 of the receptor and was approved a record 2 years and 9 months after the first dose in humans.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
